Market Place
Sourcing Support
All News #Library
Rare Diseases
Dyne To Present At AMCP 2026 For Neuromuscular Portfolio
01 Apr 2026 //
GLOBENEWSWIRE
Dyne To Pursue FDA Approval Following Positive Long-Term Data
10 Mar 2026 //
BIOSPACE
Dyne Therapeutics To Present Neuromuscular Pipeline At MDA 2026
22 Feb 2026 //
GLOBENEWSWIRE
Dyne Therapeutics` DYNE-101 Gets Orphan Status in Japan for DM1
20 Jan 2026 //
GLOBENEWSWIRE
Dyne readies FDA push after DMD exon 51 med excels in trial
08 Dec 2025 //
FIERCE BIOTECH
Dyne Therapeutics Reports Z-Rostudirsen Success In (DMD) Trial
08 Dec 2025 //
GLOBENEWSWIRE
Dyne Therapeutics To Review Duchenne Muscular Dystrophy Trial
07 Dec 2025 //
GLOBENEWSWIRE
Dyne Pharma Gets Japan Orphan Status For Dyne-251 In DMD
29 Sep 2025 //
GLOBENEWSWIRE
Fda Grants Breakthrough Status to Dyne`s DYNE-251 for Dmd
04 Aug 2025 //
GLOBENEWSWIRE
Dyne Therapeutics to Present FSHD Data at FSHD Society Congress
05 Jun 2025 //
GLOBENEWSWIRE
Dyne Therapeutics gets EMA Orphan Drug Designation for DYNE-251
24 Apr 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101
20 Sep 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Receive EMA Orphan Drug Designation for DYNE-101
25 May 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Receives EMA Orphan Drug Designation for DYNE-101
25 May 2023 //
PRESS RELEASE
Dyne Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251
23 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.